Inceptor Bio has entered an agreement to acquire Arranta Bio’s 29,000 square foot process development and GMP clinical manufacturing facility and the transfer of a core operating team to establish cell therapy processes and clinical supply for Inceptor’s planned oncology clinical trials.
Inceptor Bio's Advanced Manufacturing Platform (AMP+) will be based at the new facility in Gainesville, FL, that will be developed as a state-of-the-art cell and gene therapy GMP facility to deliver Inceptor’s programs.
"We are thrilled to welcome the experienced, talented operating team from Arranta and look forward to establishing cell therapy GMP clinical manufacturing as a key strategic capability,” said Shailesh Maingi, founder and CEO of Inceptor Bio. “This acquisition accelerates Inceptor Bio's path to the clinic for our CAR-T, CAR-M and CAR-NK programs with our lead CAR-T candidate scheduled for IND in early 2023.”
Inceptor Bio is developing multiple next-generation cell therapy platforms to address difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment (TME). Inceptor Bio currently has three cell therapy technologies: a CAR-T platform with a novel co-stimulatory technology, a CAR-M platform using macrophages with enhanced phagocytic capabilities, and a CAR-NK platform.
Arranta is a contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers. Arranta has invested in building the capabilities at the Gainesville site and expanded the team over the last two years.
"After conducting a strategic review, we concluded that the early clinical supply for clients from our Gainesville facility could be supported by our experienced team and accommodated in the over 200,000 square feet of facilities that Arranta has in Massachusetts" said Mark Bamforth, CEO at Arranta. "We are delighted that some of the technical team will transfer to Massachusetts, leaving a highly capable GMP operating team in place for Inceptor. We wish them every success in their critical mission."